Louis J. Lavigne Jr.
Louis J. Lavigne, Jr. has been a Managing Director of Lavrite, LLC, a management consulting firm specializing in the areas of corporate finance, accounting, growth strategy and management, since 2005 and Laman Partners,
LLC since 2019. Mr. Lavigne has served on the boards of directors of several public and private companies and institutions. Mr. Lavigne served in various executive capacities with Genentech, Inc. (NYSE: DNA), a biotech company, for over 20 years, including, Chief Financial Officer from 1988 to 2005, Executive Vice President from 1997 to 2005; Senior Vice President from 1994 to 1997; Vice President from 1986 to 1994; and Controller from 1983 to 1986. Mr. Lavigne was named the Best CFO in Biotech in 2005 in the Institutional Investor Survey, and in June 2006, he received the Bay Area CFO of the Year‐Hall of Fame Lifetime Achievement Award.
Mr. Lavigne since September 2009 has been a member of the board of directors and now the nominations committee of Accuray Incorporated (NASDAQ: ARAY), a radiation oncology company, and also previously served as its chairperson of the board of directors and chair of its compensation committee. He also serves as the lead director, chair of the audit committee, and member of the compensation committee of Alector, Inc. (NASDAQ:ALEC), a neurology‐ immunology company, where has been a director since October 2018 and as the lead director and chair of the audit committee of Rodan + Fields, LLC a private skincare company, where he has been a director since June 2015.
Within the last five years, Mr. Lavigne has also served as a member of the board, chair of the audit committee, and member of the compensation committee of DocuSign Inc.(NASDAQ:DOCU), an eSignature transaction management company, from July 2013 to May 2020; as a member of the board of directors and chair of the audit committee of Puppet, Inc., a private information cloud automation system management company, from December 2015 to July 2019; as a member of the board of directors of Assertio, Inc. (NASDAQ: DEPO), a specialty pharmaceutical company, from July 2013 to May 2019, where he was also chair of the compensation committee and previously the audit committee; and as a director and chair of the audit committee of NovoCure, Limited (NASDAQ:NVCR),a commercial stage oncology company, from 2013 to October 2018.
Mr. Lavigne was also a member of the board of directors, the audit committee, and the science and technology committee of Allergan, Inc. (NYSE: AGN), a technology‐driven, global health care company that provides specialty pharmaceutical products worldwide, from 2005 until its acquisition by Actavis plc in 2015; as a director and chair of the audit committee of SafeNet, Inc., a private information security company, from 2010 until its acquisition by Gemalto NV in 2015; and as a director of BMC Software, Inc. (NASDAQ: BMC), an enterprise systems software vendor, from 2004 to 2007 and from 2008 to 2013, when it was acquired by a private investor group.
From 2011 to 2019, Mr. Lavigne was a board member and member of the audit and finance committees of the UCSF Benioff Children’s Hospitals and the UCSF Children’s Hospitals Foundation where he also was the prior chair of the board.
Mr. Lavigne holds a B.S. in Finance from Babson College and an M.B.A. from Temple University.